Research Newsroom

MECOM-rearranged acute myeloid leukemia (AML) is an aggressive and hard-to-treat leukemia 

Researchers combined three inhibitors and observed cancer cell death and increased survival in lab models 

Researchers at The University of Texas MD Anderson Cancer Center have identified new potential combination therapies to target high-risk MECOM-rearranged acute...

Azacitidine is a type of targeted therapy known as a hypomethylating agent, commonly used in treating myelodysplastic syndromes (MDS)

Five-day azacitidine showed superior survival outcomes and disease control in lower-risk MDS patients 

All trial regimens evaluated were safe, but the five-day regimen offered the best balance of safety and efficacy

ORLANDO, DECEMBER 7, 2025 – Patients with lower-risk...